Jongwon Yoon
Research Subjects
Jongwon Yoon has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amalie Grenov
Francis Crick Institute, London, UK
1 shared publication - Ana Rodríguez-Ronchel
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.G., V.N., M.F.-M., P.F.-B., E.M.-R., S.M.-C., E.H.-G., M.R.-T., A.R.-R., C.R.-R., A.B., A.D., A.R.R., I.R.-V., D.S.).
1 shared publication - Anisur Rahman
Centre for Rheumatology, University College London, London, UK
1 shared publication - Anna Mikolajczak
Experimental Histopathology Science Technology Platform, The Francis Crick Institute 5 , London
1 shared publication - Bahar Artim-Esen
Division of Rheumatology, Department of Internal Medicine, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye
1 shared publication - Carola G. Vinuesa
Francis Crick Institute, London, UK
1 shared publication
Latest Publications
- Open Access
Autoantibody origins in lupus and in relapse post CAR-T therapy
Summary: Anti-CD19 chimeric antigen receptor (CAR)-T therapy induces profound remissions in lupus by depleting B cells, challenging the longstanding view that treatment-resistant disease is sustained by long-lived plasma cells. Additionally, emerging relapses highlight the need to understand how pathogenic autoantibodies arise. Using molecular antibody tagging in mice with human monogenic lupus variants, we reveal that autoantibody-producing cell cohorts are long-lived but plasma cells are short-lived, requiring continuous replenishment from proliferating precursors. The spleen acts as a major plasma cell reservoir, with perivascular localization conserved in mice and lupus patients. Relapse after anti-CD19 CAR-T occurred through newly-generated B cells rather than treatment-resistant clones. Plasma cell depletion by anti-BCMA CAR-T failed to eliminate some precursors that become autoantibody-secreting. These findings demonstrate that continuous B cell-to-plasma cell differentiation, not intrinsic plasma cell longevity, sustains pathogenic antibody responses in lupus, supporting a potential benefit of adjunctive therapies after CAR-T, particularly in genetically predisposed patients.
Open AccessAutoantibody origins in lupus and in relapse post CAR-T therapy
Summary: Anti-CD19 chimeric antigen receptor (CAR)-T therapy induces profound remissions in lupus by depleting B cells, challenging the longstanding view that treatment-resistant disease is sustained by long-lived plasma cells. Additionally, emerging relapses highlight the need to understand how pathogenic autoantibodies arise. Using molecular antibody tagging in mice with human monogenic lupus variants, we reveal that autoantibody-producing cell cohorts are long-lived but plasma cells are short-lived, requiring continuous replenishment from proliferating precursors. The spleen acts as a major plasma cell reservoir, with perivascular localization conserved in mice and lupus patients. Relapse after anti-CD19 CAR-T occurred through newly-generated B cells rather than treatment-resistant clones. Plasma cell depletion by anti-BCMA CAR-T failed to eliminate some precursors that become autoantibody-secreting. These findings demonstrate that continuous B cell-to-plasma cell differentiation, not intrinsic plasma cell longevity, sustains pathogenic antibody responses in lupus, supporting a potential benefit of adjunctive therapies after CAR-T, particularly in genetically predisposed patients.